Targeting human langerin promotes HIV-1 specific humoral immune responses

0301 basic medicine 570 QH301-705.5 [SDV]Life Sciences [q-bio] Medical Immunology Mouse models Q1 Lymphocyte Activation Antibodies T helper cells Mice 03 medical and health sciences Antigens, CD Cell differentiation Animals Humans Lectins, C-Type Biology (General) human langerin AIDS Vaccines Department of Microbiology and Immunology B cells HIV vaccines env Gene Products, Human Immunodeficiency Virus RC581-607 Immunity, Humoral 3. Good health Mannose-Binding Lectins Thomas Jefferson University Medical Microbiology Langerhans Cells HIV-1 Cytokines Immunologic diseases. Allergy humoral immune Research Article
DOI: 10.1371/journal.ppat.1009749 Publication Date: 2021-07-29T18:48:45Z
ABSTRACT
The main avenue for the development of an HIV-1 vaccine remains the induction of protective antibodies. A rationale approach is to target antigen to specific receptors on dendritic cells (DC) via fused monoclonal antibodies (mAb). In mouse and non-human primate models, targeting of skin Langerhans cells (LC) with anti-Langerin mAbs fused with HIV-1 Gag antigen drives antigen-specific humoral responses. The development of these immunization strategies in humans requires a better understanding of early immune events driven by human LC. We therefore produced anti-Langerin mAbs fused with the HIV-1 gp140z Envelope (αLC.Env). First, we show that primary skin human LC and in vitro differentiated LC induce differentiation and expansion of naïve CD4+ T cells into T follicular helper (Tfh) cells. Second, when human LC are pre-treated with αLC.Env, differentiated Tfh cells significantly promote the production of specific IgG by B cells. Strikingly, HIV-Env-specific Ig are secreted by HIV-specific memory B cells. Consistently, we found that receptors and cytokines involved in Tfh differentiation and B cell functions are upregulated by LC during their maturation and after targeting Langerin. Finally, we show that subcutaneous immunization of mice by αLC.Env induces germinal center (GC) reaction in draining lymph nodes with higher numbers of Tfh cells, Env-specific B cells, as well as specific IgG serum levels compared to mice immunized with the non-targeting Env antigen. Altogether, we provide evidence that human LC properly targeted may be licensed to efficiently induce Tfh cell and B cell responses in GC.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (51)
CITATIONS (8)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....